"Talent Accessibility Plays a Pivotal Role"
In an interview with Edgardo Hernandez, Executive Vice President at Eli Lilly and Company and President of Manufacturing Operations, the pharmaceutical giant announced plans for a new drug product site in Alzey, Germany.
The new facility, set to become one of the largest combination product manufacturers globally, will focus on sterile filling for parenteral products and device assembly. It is expected to employ up to 1,000 employees during its operational phase, tapping into the local talent pool and proximity to equipment manufacturers, allowing for quick same-day service.
The strategic location near logistics hubs will enable efficient resupply of medicines to numerous countries, serving patients globally. The new site in Alzey will primarily employ engineers, operators, scientists, and other professionals such as microbiologists, chemists, and pharmacists.
Lilly prioritizes regions that safeguard its intellectual property when evaluating investment opportunities. The company has launched an investment offensive worth more than $55 billion since 2020, including the construction of eight new manufacturing sites in the US and two in Europe.
Lilly Deutschland GmbH, the German subsidiary of Eli Lilly and Company, has been working closely with the German authorities to navigate the construction process efficiently. The company is still looking for support for the interior work on the buildings at the Alzey facility and is also rebuilding its capabilities for small molecules, as the pipeline had previously shifted to monoclonal antibodies, requiring increased monoclonal capacity.
Edgardo Hernandez, who holds bachelor's and master's degrees in chemical engineering from the University of Puerto Rico and North Carolina State University, respectively, emphasised Lilly's commitment to hiring early career individuals and experienced professionals for their workforce. The company also prioritises cultural fit when recruiting talent and provides necessary technical training for candidates who align with their values.
Moreover, Lilly is looking to maintain strong partnerships with educational institutions to foster interest in STEM careers. The new investments focus on building for the future, particularly in the US, where Lilly is developing new platforms for drug substances, ADCs (antibody-drug conjugates), and RNA.
As the construction of the Alzey facility progresses, the community can look forward to new job opportunities and Lilly's continued commitment to delivering high-quality medicines to patients worldwide.
Read also:
- Overcoming Yielding Regulations Hurdles in Indian Export Sector for EU Markets
- Shaping production and consumption tendencies via cosmetic certification
- Increased Investment in AI, Machine Learning, Internet of Things, and Quantum Computing to Propel Growth in the Digital Economy (2020 Budget)
- Deteriorated residence designed for trainees
